Meet Yao Liu, MD, Glaucoma sub-specialist at the University of Wisconsin Department of Ophthalmology and Visual Sciences
“As a glaucoma specialist, I see far too many patients who suffer from severe vision loss that does not respond to traditional glaucoma treatments aimed at lowering eye pressure. There is an urgent need to identify other treatable glaucoma risk factors, new medications, new low-cost interventions to prevent glaucoma and new methods for detecting glaucoma progression. My long-term goal is to reduce vision loss from glaucoma.”
Dr. Liu’s current glaucoma studies include:
Macular Pigment as a Glaucoma Risk Factor in CAREDS2
In this multi-center study, the researchers will determine whether low macular pigment levels may be a modifiable risk factor for glaucoma by assessing glaucoma incidence among more than 800 women followed for over a decade in the Carotenoids in Age-Related Eye Disease Study 2 (CAREDS2). This research is funded by the National Institutes of Health/National Eye Institute, University of Wisconsin ICTR Pilot Award and the American Glaucoma Society MAPS Award.
Multifocal electroretinograms and multifocal visual evoked potentials in glaucoma
This pilot study seeks to evaluate the use of multifocal electroretinograms and multifocal visual evoked potentials as objective measures of visual function among patients with glaucoma. The results of these tests will be compared and correlated to those obtained from visual field testing and OCT imaging.
Mercury 1 Glaucoma Trial
A randomized, multi-center study assessing the safety and efficacy of PG324 Ophthalmic Solution compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solution, 0.005% in patients with high eye pressure. This study is supported by Aerie Pharmaceuticals.